InvestSMART

Argent Biopharma Limited (ASX:RGT)

ALERT: Price-sensitive ASX Announcement for RGT
Current share price for RGT : $0.025 -0.02 (-44.44%)+
Announcement
Release
6 Aug 2026 9:14AM
Price at Release
$0.045
Full Release
download
Summary
Argent BioPharma Limited has initiated a U.S. veterinary development programme for CannEpil®, a cannabinoid therapy. This programme, led by Splash Beverage Group and Lupvindol Biosciences, focuses on developing treatments for companion-animal oncology and chronic pain management. The effort is spearheaded by Dr. Hunter Land, a former executive at GW Pharmaceuticals, with plans to navigate the U.S. FDA Center for Veterinary Medicine's regulatory processes. Argent BioPharma retains its intellectual property rights and aims to enhance CannEpil®'s presence in the veterinary healthcare sector, marking a significant step in broadening its therapeutic applications.
Key Points
  • Argent BioPharma Ltd announced the commencement of a U.S. veterinary development programme for CannEpil®.
  • The programme is led by Splash Beverage Group and Lupvindol Biosciences.
  • Dr. Hunter Land, former GW Pharmaceuticals executive, is leading the development team.
  • The focus is on companion-animal oncology and chronic pain management.
  • Development will proceed through the U.S. FDA Center for Veterinary Medicine.
  • Argent BioPharma retains ownership of CannEpil® intellectual property.
  • The programme is part of Argent BioPharma's strategy to expand CannEpil® into veterinary healthcare.
  • The initiative aims to strengthen CannEpil®’s regulatory and commercial pathways in the U.S.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.